Advances and Prospects in the Treatment of Pancreatic Cancer
Top Cited Papers
Open Access
- 1 July 2023
- journal article
- review article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 18, 3973-3988
Abstract
Pancreatic cancer is a highly malignant and incurable disease, characterized by its aggressive nature and high fatality rate. The most common type is pancreatic ductal adenocarcinoma (PDAC), which has poor prognosis and high mortality rate. Current treatments for pancreatic cancer mainly encompass surgery, chemotherapy, radiotherapy, targeted therapy, and combination regimens. However, despite efforts to improve prognosis, and the 5-year survival rate for pancreatic cancer remains very low. Therefore, it’s urgent to explore novel therapeutic approaches. With the rapid development of therapeutic strategies in recent years, new ideas have been provided for treating pancreatic cancer. This review expositions the advancements in nano drug delivery system, molecular targeted drugs, and photo-thermal treatment combined with nanotechnology for pancreatic cancer. It comprehensively analyzes the prospects of combined drug delivery strategies for treating pancreatic cancer, aiming at a deeper understanding of the existing drugs and therapeutic approaches, promoting the development of new therapeutic drugs, and attempting to enhance the therapeutic effect for patients with this disease.Keywords
This publication has 168 references indexed in Scilit:
- Diverse roles of GSK-3: Tumor promoter–tumor suppressor, target in cancer therapyAdvances in Biological Regulation, 2014
- The ErbB/HER family of protein-tyrosine kinases and cancerPharmacological Research, 2014
- Biodegradable Nanocapsules as siRNA Carriers for Mutant K‐Ras Gene Silencing of Human Pancreatic Carcinoma CellsSmall, 2013
- Biocompatibility of Mesoporous Silica NanoparticlesChemical Research in Toxicology, 2012
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancerBritish Journal of Cancer, 2012
- Albumin-based nanoparticles as potential controlled release drug delivery systemsJournal of Controlled Release, 2012
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Clinical Oncology, 2010
- Deletion of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3 Deletion in Mouse EmbryosMolecular and Cellular Biology, 2008
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005